Cory M Johannessen

age ~44

from West Sand Lake, NY

Get Report

Also known as:

Cory H Johannessen
Adrian C Hayday

Connected to:

Cory Johannessen Phones & Addresses

West Sand Lake, NY
17 Brown Ave, Roslindale, MA 02131
Jamaica Plain, MA
78 Geiser Rd, Wynantskill, NY 12198 • 5182833556

Work

Company:

Novartis institutes for biomedical research (nibr)
Mar 2019
Position:

Senior investigator

Education

Degree:

Doctorates, Doctor of Philosophy
School / High School:

Harvard University
2003 to 2008
Specialities:

Genetics, Biology

Skills

Molecular Biology • Molecular Cloning • Cell Biology • Cancer Research • Western Blotting • Cell Culture • Genomics • Biochemistry • Cell • Pcr • Qpcr • Immunohistochemistry • Protein Expression • Lifesciences • Animal Models

Industries

Research

Resumes

Senior Investigator

view source

Location:

Boston, MA

Industry:

Research

Work:

Novartis Institutes For Biomedical Research (Nibr)
Senior Investigator
Broad Institute Oct 2008 - Nov 2015
Instructor
Broad Institute Oct 2008 - Nov 2015
Senior Group Leader, Drug Resistance and Combinations
Dana-Farber Cancer Institute Oct 2008 - May 2014
Postdoctoral Associate
Harvard Medical School Sep 2003 - Sep 2008
Graduate Student

Education:

Harvard University 2003 - 2008
Doctorates, Doctor of Philosophy, Genetics, Biology Wheaton College Massachusetts 1997 - 2001
Bachelors, Bachelor of Arts, Biology

Skills:

Molecular Biology
Molecular Cloning
Cell Biology
Cancer Research
Western Blotting
Cell Culture
Genomics
Biochemistry
Cell
Pcr
Qpcr
Immunohistochemistry
Protein Expression
Lifesciences
Animal Models

Us Patents

Methods Of Diagnosing And Treating Cancer In Patients Having Or Developing Resistance To A First Cancer Therapy
view source
US Patent:

20130059851, Mar 7, 2013
Filed:

Mar 9, 2011
Appl. No.:

13/583056
Inventors:

Levi A. Garraway - Newton MA, US
Cory M. Johannessen - Roslindale MA, US
Assignee:

DANA-FARBER CANCER INSTITUTE, INC. - Boston MA
International Classification:

A61K 31/437
C40B 30/04
G01N 33/574
C40B 30/06
A61K 31/4439
A61P 35/00
A61K 31/444
A61K 31/167
A61K 31/166
A61K 31/353
A61K 31/5377
A61K 31/18
C12Q 1/68
A61K 31/44
US Classification:

5142352, 435 611, 506 9, 435 792, 435 74, 506 10, 514338, 514346, 514341, 514300, 514619, 514394, 514456, 5142362, 514605
Abstract:

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.

Methods And Compositions For Studying Cell Evolution
view source
US Patent:

20230083163, Mar 16, 2023
Filed:

Nov 22, 2022
Appl. No.:

18/057809
Inventors:

- Cambridge MA, US
- Boston MA, US
David Feldman - Cambridge MA, US
Cory Johannessen - Cambridge MA, US
International Classification:

A61F 13/551
A41D 19/00
C12N 15/10
C12N 15/113
Abstract:

The subject matter disclosed herein is generally directed to methods and compositions for tagging cells of interest, tracking evolution of the tagged cells, and recovering the original tagged cells for further study. Specifically, cells are tagged with a DNA construct encoding a barcode sequence comprising a guide sequence. Barcoded cells can then be recovered using a reporter construct having CRISPR target sequences specific for the cell having a barcode of interest.

Synergistic Drug Combinations Predicted From Genomic Features And Single-Agent Response Profiles
view source
US Patent:

20210069230, Mar 11, 2021
Filed:

Apr 12, 2019
Appl. No.:

17/046560
Inventors:

- Cambridge MA, US
Cory Johannessen - Cambridge MA, US
Assignee:

THE BROAD INSTITUTE, INC. - Cambridge MA
International Classification:

A61K 31/7088
A61K 31/55
A61K 31/4709
A61K 31/192
A61K 31/4525
A61K 31/325
A61K 31/215
A61K 31/167
A61K 31/381
A61K 31/341
A61K 31/18
A61K 31/343
A61K 31/357
A61K 31/366
A61K 31/695
A61K 31/454
A61K 31/453
A61K 31/506
A61K 31/519
A61K 31/5025
A61K 31/4985
A61K 31/473
A61K 31/7048
A61K 31/496
A61K 31/352
A61K 31/704
A61K 31/4045
A61K 31/138
A61K 31/365
A61K 31/12
A61K 31/5377
A61K 31/52
A61K 31/553
A61K 31/661
A61K 31/4439
A61K 31/4745
A61K 31/437
A61K 31/4453
A61K 31/53
A61K 31/4704
A61K 31/47
A61K 31/416
A61K 31/4725
A61K 31/4402
A61P 35/00
Abstract:

The present disclosure relates to discovery of specific synergistic drug combinations and mechanisms of drug resistance. Compositions involving newly-identified drug combinations as well as diagnostic and therapeutic methods related to such discoveries are provided.

Methods Of Diagnosing And Treating Cancer In Patients Having Or Developing Resistance To A First Cancer Therapy
view source
US Patent:

20170268069, Sep 21, 2017
Filed:

Apr 5, 2017
Appl. No.:

15/480126
Inventors:

Levi A. Garraway - Newton MA, US
Cory M. Johannessen - Roslindale MA, US
International Classification:

C12Q 1/68
A61K 31/4184
C12N 9/12
Abstract:

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2/COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.